Journal of Clinical Pharmacy and Therapeutics最新文献

K. M. A. Zinnah, A. N. Munna, J.-W. Seol, and S.-Y. Park, “Impaired Autophagic Flux by Citalopram Inhibits DR5 Degradation and Increases TRAIL-Mediated Apoptosis,” Journal of Clinical Pharmacy and Therapeutics, vol. 2025 (2025). https://doi.org/10.1155/jcpt/7538839.

In the article titled “Impaired Autophagic Flux by Citalopram Inhibits DR5 Degradation and Increases TRAIL-Mediated Apoptosis,” there was an error in Figure 1(j) related to an incorrect image being used to represent the morphology of the Calu-3 cells.

This error was introduced by the authors during figure assembly and should be corrected as follows:

We apologize for this error.

Chimeric antigen receptor T-cell therapy (CAR-T) is an emerging therapy for malignancies, including refractory B-cell lymphoma, follicular lymphoma, multiple myeloma, and chronic lymphocytic leukemia. Postmarketing monitoring is essential to ensure the rational administration of CAR-T because of its high occurrence rate of adverse events. Thus, we collected the adverse event reports from the FAERS database between the first quarter of 2017 and the second quarter of 2025. Disproportion analysis methods, including the reporting odds ratio and information component, were used to identify potential hematological AEs associated with CAR-T therapy. A total of 47,118,226 reports were analyzed, and 99,497 adverse events associated with CAR-T-cell therapy were identified. We found 11,689 hematological adverse events accounted for 11.75% of the total adverse events, of which cytopenia (ROR025 = 33.87, IC025 = 4.95), hemophagocytic lymphohistiocytosis (HLH, ROR025 = 28.20, IC025 = 4.71), and myelodysplastic syndrome (MS, ROR025 = 34.41, IC025 = 4.98) were highly underrated in the real world. All six CAR-T products were associated with hematological adverse events, and the typical hematological adverse events varied among different products. A high proportion and frequency of death outcomes were identified after CAR-T-related hematological adverse events, such as thrombocytopenia, HLH, and cytopenia. Cytokine release syndrome frequently overlapped with hematological adverse events, including cytopenia, HLH, and thrombocytopenia. Our results may help clinicians identify rare but potentially fatal hematological AEs at an early stage, effectively reducing the risk of lethal hematological toxicity of CAR-T therapy.

Remimazolam has shown safety and efficacy in providing sedation during gastroscopy, but research on its specific clinical dosage is limited. This study aimed to determine the 90% effective dose (ED₉₀) of remimazolam when used with a low dose of alfentanil for inducing sedation in adult patients undergoing gastroscopy. Fifty adult participants underwent upper gastrointestinal (GI) endoscopy with anesthesia via intravenous boluses of remimazolam and alfentanil (4 μg/kg). The initial remimazolam dose was 0.2 mg/kg, adjusted using the biased coin up-and-down (BCUD) sequential method. The ED₉₀ of remimazolam, administered with 4 μg/kg alfentanil, was found to be 0.2375 mg/kg (95% CI: 0.1500–0.2725). Hemodynamics remained stable, with no significant adverse events and high satisfaction scores from patients, anesthesiologists, and endoscopists (4.90 ± 0.043, 4.92 ± 0.039, and 4.92 ± 0.039, respectively, on a 5-point scale). The combination of remimazolam and low-dose alfentanil is safe and effective for adult upper GI endoscopy.

Trial Registration: Chinese Registry of Clinical Trials: ChiCTR2200062535

Hypersensitivity reactions (HSRs) can be a significant barrier to a patient’s cancer treatment journey. HSRs caused by immunomodulating agents, specifically lenalidomide (LEN) can be overwhelmingly distressful, paradoxically depriving patients of access to a clinically meaningful drug. Based on our historical clinical experiences, we have learned that the rapid desensitization protocol (RDP), when executed precisely, can enable patients to successfully resume LEN treatment. This served as the impetus for initiating our prospective study. We consecutively enrolled 10 patients diagnosed with plasma cell disease who had experienced a previous HSR specifically with LEN. After fully recovering from their initial reactions, patients underwent a controlled 10–12 steps incremental increase in drug dosage administration, followed by daily resumption of LEN over a 90-day period. All 10 (100%) patients successfully completed the protocol and continued on further LEN treatment cycles, although 1 patient voluntarily chose to withdraw from the study due to recurrent symptoms after receiving 2 doses of LEN. Three (30%) patients remained symptom-free throughout the follow-up period. Six (60%) patients experienced mild and short-lived HSR reactivation; however, all had the ability to take LEN for the majority of the study period. RDP enables patients to continue taking LEN and maintains the health-related quality of life (HR-QoL) by reducing the occurrence of HSR. RDP empowers patients to participate in future clinical trialsinvolving novel treatments that contain LEN as a backbone therapy, opportunities they would have otherwise been ineligible for.